Skip to main content

Table 3 Performance of PDACatch, CA 19-9 and the combined model to classify all cases of the training and validation sets that have CA19-9 levels (bootstrapped 1000 repetitions at 95% CIs)

From: Noninvasive detection of pancreatic ductal adenocarcinoma using the methylation signature of circulating tumour DNA

 

PDACatch

CA19-9

Combined: PDACatch + CA19-9

 

PDAC

AUC (CI)

Sensitivity (CI)

AUC (CI)

Sensitivity (CI)

AUC (CI)

Sensitivity (CI)

pvalue for AUC

I:N=25

0.92 (0.85–0.97)

0.8 (0.59–0.93)

0.85 (0.75–0.93)

0.68 (0.46–0.85)

0.93 (0.88–0.98)

0.92 (0.74–0.99)

1.61E−06

II:N=44

0.88 (0.81–0.93)

0.68 (0.52–0.81)

0.88 (0.81–0.94)

0.75 (0.6–0.87)

0.92 (0.87–0.96)

0.77 (0.62–0.89)

5.42E−05

I/IIA:N=34

0.91 (0.84–0.96)

0.76 (0.59–0.89)

0.86 (0.78–0.93)

0.71 (0.53–0.85)

0.92 (0.86–0.97)

0.88 (0.73–0.97)

2.61E−05

I/II:N=69

0.89 (0.83–0.94)

0.72 (0.6–0.83)

0.87 (0.8–0.92)

0.72 (0.6–0.83)

0.93 (0.88–0.97)

0.83 (0.72–0.91)

1.59E−07

III/IV:N= 23

0.94 (0.89–0.98)

0.87 (0.66–0.97)

0.94 (0.88–0.99)

0.91 (0.72–0.99)

0.97 (0.93–0.99)

0.96 (0.78–1)

6.02E−06

All stages:N=92a

0.91 (0.85–0.95)

0.76 (0.66–0.84)

0.89 (0.83–0.94)

0.77 (0.67–0.85)

0.94 (0.89–0.97)

0.86 (0.77–0.92)

1.00E−07

  

Specificity (CI)

 

Specificity (CI)

 

Specificity (CI)

 

Healthy:N=37

 

0.89 (0.75–0.97)

 

0.89 (0.75–0.97)

 

0.89 (0.75–0.97)

 
  1. p values were calculated by the DeLong test
  2. PDAC pancreatic ductal adenocarcinoma, CA19-9 carbohydrate antigen 19-9, CI confidence interval
  3. aTwo PDAC cases had no stage information